Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.77 |
| ▸ | IDH2 | P48735 | 16/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21799043 | 1.00 | IDH1 (0.77) | IDH1IDH2 | |
| SCHEMBL29765342 | 1.00 | IDH1 (0.77) | IDH1IDH2 | |
| SCHEMBL21799085 | 1.00 | IDH1 (0.77) | IDH1IDH2 | |
| SCHEMBL20289919 | 1.00 | IDH1 (0.77) | IDH1IDH2 | |
| SCHEMBL20289879 | 1.00 | IDH1 (0.77) | IDH1IDH2 | |
| SCHEMBL24170400 | 0.97 | IDH1 (0.72) | IDH1IDH2 | |
| SCHEMBL23625845 | 0.92 | IDH1 (0.66) | IDH1IDH2 | |
| SCHEMBL21799147 | 0.92 | IDH1 (0.75) | IDH1IDH2 | |
| SCHEMBL21799145 | 0.92 | IDH1 (0.75) | IDH1IDH2 | |
| SCHEMBL20289610 | 0.92 | IDH1 (0.75) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109075-B | Mutant IDH1 and IDH2 inhibitors | 伊莱利利公司 | 2024-09-20 | — | — | CN | disclosed |
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-04-18 | — | — | US | disclosed |
| WO-2023059582-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | IDH1 2/4885IDH2 1/4885 |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | IDH1 2/4885IDH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.